Centene Corporation's Stock Analysis

Centene to Present at Deutsche Bank Healthcare Summit

Centene Corporation will participate in the Deutsche Bank 2025 Healthcare Summit on September 11, 2025, at 8:00 a.m. EDT. Management will discuss the company’s business and financial results through August, aligning with its previously issued forecast of approximately $1.75 adjusted diluted earnings per share (EPS). A live audio webcast of the presentation will be available, along with a replay on the company's website.

The company is providing non-GAAP financial measures to help investors assess its ongoing operations and performance consistently. These measures exclude certain expenses, allowing for a clearer understanding of core performance over time. However, Centene cautions that these non-GAAP measures may differ from those used by other companies, and it encourages investors to review its consolidated financial statements for a complete picture of its financial health.

Sep 10, 2025 21:40:56

Centene Director Thomas R. Greco Resigns Effective August 2025

Director Thomas R. Greco has resigned from Centene Corporation, effective August 22, 2025. His resignation is attributed to increased professional responsibilities following his appointment as CEO of FleetPride, Inc. There were no disputes or disagreements between Mr. Greco and the Company or its Board regarding operations or policies.

Following Mr. Greco's departure, the Board of Directors will be reduced to nine members. This change in the board composition may impact the governance structure of the Company as it continues its operations.

Aug 15, 2025 16:29:37

Centene Director Resignation Reduces Board Size to Ten

Wayne S. DeVeydt has resigned from his position as a director of Centene Corporation, effective immediately as of August 1, 2025. His resignation was not due to any disputes or disagreements with the company or its Board of Directors.

Following Mr. DeVeydt's departure, the Board has adjusted its composition, reducing the number of directors to ten. This change may impact the governance structure of the company.

Aug 04, 2025 16:36:48

Centene Reports Second Quarter 2025 Financial Results

Centene Corporation reported a diluted loss per share of $(0.51) for the second quarter of 2025, with an adjusted diluted loss per share of $(0.16). The company experienced an 18% increase in premium and service revenues, reaching $42.5 billion, primarily due to growth in its Medicare and Marketplace segments. However, the health benefits ratio rose to 93.0% from 87.6% in the previous year, attributed to increased medical costs and a reduction in risk adjustment revenue estimates. Operating cash flow was reported at $1.8 billion, reflecting improved timing of pharmacy rebate remittances.

As of June 30, 2025, Centene maintained cash, investments, and restricted deposits totaling $37.5 billion, with medical claims liabilities amounting to $20.1 billion. The company’s total debt stood at $17.6 billion, with no borrowings on its $4 billion revolving credit facility. Centene's management is focused on addressing the trends impacting performance and aims to adapt to the evolving market landscape to deliver value to its stakeholders.

Jul 24, 2025 21:46:22

Centene Corporation Withdraws 2025 Earnings Guidance Amid Market Changes

Centene Corporation has withdrawn its previous guidance for 2025 earnings per share due to unexpected changes in the Health Insurance Marketplace. An analysis of preliminary data from 22 of its 29 Marketplace states revealed lower market growth and higher morbidity rates than anticipated, leading to an estimated reduction of approximately $1.8 billion in expected risk adjustment revenue, which corresponds to an adjusted diluted EPS impact of about $2.75. The company also expects further reductions for the remaining states based on these observed trends.

Additionally, Centene has started the process of refiling its 2026 Marketplace rates to reflect the higher morbidity projections. While the final 2024 risk adjustment results were in line with expectations, the company noted a step-up in medical costs within its Medicaid business, particularly in areas such as behavioral health and high-cost drugs. The second quarter 2025 results will be reported on July 25, 2025, providing further insights into the company's performance.

Jul 01, 2025 16:43:52

Centene Reports 28% EPS Growth and Revenue Increase

Centene Corporation announced its financial results for the first quarter of 2025, reporting an adjusted diluted earnings per share (EPS) of $2.90, which is a 28% increase from $2.26 in the same quarter of 2024. The company also experienced a 17% year-over-year growth in premium and service revenues, totaling $42.5 billion, driven by significant increases in Marketplace and Medicare membership. Additionally, Centene raised its 2025 premium and service revenues guidance by $6.0 billion, reflecting strong performance in enrollment and member retention.

The company reported total revenues of $46.6 billion for the quarter and a health benefits ratio of 87.5%. The selling, general and administrative (SG&A) expense ratio improved to 7.9%, down from 8.9% in the previous year. Cash flow from operations was $1.5 billion, and total debt stood at $18.3 billion. Centene's subsidiaries secured contracts in Nevada and Illinois to continue providing Medicaid and Medicare services, which are expected to begin in January 2026. The company is also recognized as one of America's Most Innovative Companies by Fortune® Magazine for the second consecutive year.

Apr 24, 2025 20:19:02

Centene Appoints Kenneth Y. Tanji to Board of Directors

Centene Corporation has appointed Kenneth Y. Tanji to its Board of Directors, increasing the board's size to 12 members. Mr. Tanji brings over 30 years of financial expertise, particularly in capital optimization and strategic acquisitions, which Centene's CEO believes will be beneficial as the company addresses healthcare challenges. His prior experience includes serving as CFO at Prudential Financial and teaching corporate finance at Rutgers University.

While the appointment adds a seasoned professional to the board, there are no specific financial metrics or performance updates provided in the release. The focus remains on Mr. Tanji's qualifications and potential contributions to Centene's mission of enhancing healthcare services for underserved populations, without detailing any immediate impacts on the company's financial standing.

Feb 24, 2025 16:17:11

Centene Corporation Reports $6.31 EPS for 2024

Centene Corporation announced a diluted earnings per share (EPS) of $6.31 for 2024, with adjusted diluted EPS rising to $7.17, reflecting a 7% increase from the previous year. The company experienced a 12% increase in Marketplace membership and a significant 50% rise in Medicare Prescription Drug Plan (PDP) membership compared to the prior quarter. Additionally, Centene executed $3.0 billion in share repurchases throughout the year and increased its 2025 revenue guidance by $4.0 billion, primarily due to Medicaid revenue and strong Medicare enrollment performance.

On the downside, Centene faced challenges with a health benefits ratio (HBR) of 89.6% for the fourth quarter, slightly higher than the previous year, attributed to increased acuity in Medicaid. The SG&A expense ratio was reported at 8.9%, indicating a rise compared to the previous year, driven by growth in the Marketplace business. Furthermore, cash flow used in operations for the fourth quarter was negative at $587 million, largely due to timing issues related to receivables, and total debt stood at $18.5 billion.

Feb 03, 2025 18:39:52

Centene Corporation Projects 2025 EPS Over $7.25

Centene Corporation announced its financial guidance for 2025, projecting an adjusted diluted earnings per share (EPS) of greater than $7.25, which indicates over 6% growth from the previous year. The company reaffirmed its 2024 adjusted diluted EPS guidance of greater than $6.80, alongside total revenue expectations ranging from $166.5 billion to $169.5 billion. Centene emphasized its commitment to serving over 28 million members, particularly those from medically complex and underserved backgrounds, and highlighted improvements in core operations and customer experience over the past three years.

However, the company also provided a detailed outlook that includes a health benefits ratio (HBR) of 88.4% to 89.0% and a selling, general, and administrative (SG&A) expense ratio of 8.1% to 8.7% for 2025. The guidance includes various financial metrics that suggest potential challenges in managing expenses and maintaining profitability, particularly with the ongoing fluctuations in healthcare costs and regulatory changes. This context underscores the operational uncertainties Centene may face in achieving its projected financial outcomes.

Dec 11, 2024 20:04:28

Centene Corporation Reports Strong Q3 2024 Financial Results

Centene Corporation announced positive financial results for the third quarter of 2024, with adjusted earnings per share reaching $1.62, up from $1.36 in the same period last year. The company experienced a 6% increase in premium and service revenues, totaling $36.9 billion, driven by growth in Medicaid and Marketplace membership. Notably, membership in Medicare Prescription Drug Plans surged by 49%, indicating strong market positioning. Additionally, Centene successfully repurchased $1.2 billion of its shares in the quarter, reflecting confidence in its financial health and future performance.

On the downside, the company's health benefits ratio increased to 89.2%, indicating higher costs associated with Medicaid services, which could impact profitability. Furthermore, cash flow used in operations was negative $978 million, primarily due to settlements related to Marketplace risk adjustments and outstanding Medicaid rate increases. Despite these challenges, Centene remains optimistic about its long-term growth prospects and has reaffirmed its adjusted diluted EPS guidance for the year.

Oct 24, 2024 19:26:12